Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Type
Public
HQ
Princeton, US
Founded
2002
Size (employees)
90 (est)
Advaxis was founded in 2002 and is headquartered in Princeton, US

Key People at Advaxis

Daniel J. O'Connor

Daniel J. O'Connor

President, Chief Executive Officer and Director
Thomas A. Moore

Thomas A. Moore

Chairman / CEO
Thomas J. McKearn

Thomas J. McKearn

Director
Roni A. Appel

Roni A. Appel

Director
Richard Berman

Richard Berman

Director
Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has an office in Princeton
Princeton, US (HQ)
305 College Rd E

Advaxis Data and Metrics

Advaxis Financial Metrics

Advaxis's revenue was reported to be $4 m in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

4 m

Net income (FY, 2016)

(73.6 m)

EBIT (FY, 2016)

(76.5 m)

Market capitalization (25-May-2017)

350.6 m

Closing share price (25-May-2017)

9.2

Cash (31-Oct-2016)

112.8 m
Advaxis's current market capitalization is $350.6 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.9 m1 m4 m

Revenue growth, %

(46%)

Operating expense total

71.4 m20.5 m48.7 m80.5 m

EBIT

(69.5 m)(19.5 m)(48.7 m)(76.5 m)

EBIT margin, %

(3730%)(1954%)(1915%)

Interest expense

987.7 k5.3 k

Interest income

331.5 k

Income tax expense

725.2 k2.4 m2.5 m

Net Income

(67.5 m)(16.5 m)(47 m)(73.6 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2016

Cash

20.6 m17.6 m112.8 m

Accounts Receivable

80.1 k

Inventories

Current Assets

20.8 m20.5 m159.9 m

Total Assets

23.6 m23.4 m169 m

Accounts Payable

3.8 m1.4 m1.7 m

Current Liabilities

4.9 m2.7 m27.7 m

Additional Paid-in Capital

88.5 m107.6 m327.1 m

Retained Earnings

(87 m)(207.7 m)

Total Equity

20.6 m119.3 m

Financial Leverage

1.1 x1.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(20 m)(16.5 m)(73.6 m)

Depreciation and Amortization

19.3 k27.6 k283.5 k

Accounts Receivable

65.2 k

Inventories

Accounts Payable

(1.9 m)8.4 m

Cash From Operating Activities

(8.7 m)(17 m)49 m(9.1 m)

Purchases of PP&E

(24.6 k)(24.6 k)(3.2 m)

Cash From Investing Activities

(295.7 k)(439.7 k)1.6 m

Short-term Borrowings

(690.8 k)

Cash From Financing Activities

29.6 m14.5 m53.7 m

Interest Paid

103.4 k

Income Taxes Paid

50 k
Numbers are in $, USDY, 2016

Revenue/Employee

83.2 k

Financial Leverage

1.4 x

Advaxis Market Value History

Advaxis Online and Social Media Presence

Advaxis Company Life and Culture

You may also be interested in